考究　循環器診療の奥深さを学ぶ黒のカルテ

出版社： メディカ出版
著者：
発行日： 2021-04-01
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784840475525
電子書籍版： 2021-04-01 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する
特記事項：
  • 【電子書籍】著作権者の意向により電子版では非掲載の画像がございます

商品紹介

一筋縄でいかない症例、落とし穴にはまった症例、 悩ましい症例等BACCHUS研究会の実際の討論を紙面に再現。 「王道」と「考究」は互いに参照・補完する構成で本書は特に 循環器専門医を目指す後期研修医、総合診療医、救急・集中治療専門医にうってつけ。

目次

  • ＜Chapter 1＞ん？この心不全、何かがおかしい…
    【匠の視点1】血行動態評価に強くなろう！①：Swan-Ganzカテーテルを使いこなす
    【匠の視点2】冠循環を理解して臨床に活かそう

    ＜Chapter 2＞心囊穿刺後に急変！？まさか、心“臓”穿刺…？
    【匠の視点3】身体所見から血行動態を考えよう：心タンポナーデ
    【匠の視点4】血行動態評価に強くなろう！②：右室梗塞を診断する

    ＜Chapter 3＞B型解離で一安心？
    〔Column 1〕漢方専門医に聞いてみよう！：初心者でも使える漢方薬処方のコツ

    ＜Chapter 4＞骨折と心不全の不思議な関係
    〔Column 2〕心不全におけるACPは一日にしてならず

    ＜Chapter 5＞左房に浮かぶ2つの物体“いつとるの？今でしょ！”
    〔Column 3〕NST専門医に聞いてみよう！：重症患者の経腸栄養

    ＜Chapter 6＞突然の胸痛、そんなとこ裂けるの！？

    ＜Chapter 7＞水に浮かぶ心臓。その理由は？
    〔Column 4〕膠原病専門医に聞いてみよう！：循環器診療でみる膠原病疾患の診かた・考え方

    ＜Chapter 8＞繰り返す急性肺水腫 その原因は？
    〔Column 5〕冠攣縮：本当にわかっていますか？

    ＜Chapter 9＞心不全の裏ボスを暴け！～ACS症例で考えること～
    〔Column 6〕腎臓専門医に聞いてみよう!：慢性腎臓病患者の急性心不全

    ＜Chapter 10＞あなたならどうする、すぐに手術？それとも…

    ＜Chapter 11＞どっちの治療が先？
    〔Column 7〕「白」「黒」診断：心臓MRIこれだけは！

    ＜Chapter 12＞突然の呼吸困難・ショック、次の一手はもちろん…カテコラミン？？

    ＜Chapter 13＞発熱、腰痛といえば解熱鎮痛薬！？聴診してます？
    〔Column 8〕感染性心内膜炎up to date

    ＜Chapter 14＞ただの風邪だと思っていたのに
    【匠の視点5】補助循環に強くなろう！

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter 1 ん ? この心不全、何かがおかしい…

P.26 掲載の参考文献
1) 日本循環器学会合同研究班参加学会. 2014-2015年度活動. 心臓サルコイドーシスの診療ガイドライン (2016年版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_terasaki_h.pdf (2021年1月閲覧)
 
2) 日本循環器学会合同研究班参加学会. 2019年度活動. 心アミロイドーシス診療ガイドライン (2020年版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kitaoka.pdf (2021年1月閲覧)
 
3) Martinez-Naharro, A. et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 12, 2019, 810-9.
PubMed
4) Benson, MD. et al. Amyloid nomenclature 2018 : recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 25, 2018, 215-9.
PubMed
5) Wechalekar, AD. et al. Systemic amyloidosis. Lancet. 387, 2016, 2641-54.
PubMed
6) Buxbaum, JN. et al. Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J. 26, 2012, 2283-93.
 
7) Zhao, L. et al. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 52, 2013, 1913-26.
PubMed
8) Maurer, MS. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 379, 2018, 1007-16.
PubMed
9) Gillmore, JD. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 133, 2016, 2404-12.
PubMed
10) Rapezzi, C. et al. Systemic cardiac amyloidosis : disease profiles and clinical courses of the 3 main types. Circulation. 120 (13), 2009, 1203-12.
PubMed
11) Lee, GY. et al. Cardiac amyloidosis without increased left ventricular wall thickness. Mayo Clin Proc. 89 (6), 2014, 781-9.
PubMed
P.40 掲載の参考文献
1) Camici, PG. et al. Coronary microvascular dysfunction. NEJM. 356, 2007, 830-40.
PubMed
2) de Waard, GA. et al. Coronary autoregulation and assessment of stenosis severity without pharmacological vasodilation. Eur Heart J. 39 (46), 2018, 4062-71.
PubMed
3) Klocke, FJ. Measurements of coronary flow reserve : defining pathophysiology versus making decisions about patient care. Circulation. 76 (6), 1987, 1183-9.
PubMed
4) Gould, KL. et al. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol. 33 (1), 1974. 87-94.
PubMed
5) Robert, O. Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine. 9th ed. Amsterdam, Elsevier, 2011, 1,051.
 
6) Kern, MJ. et al. From research to clinical practice : current role of intracoronary physiologically based decision making in the cardiac catheterization laboratory. J Am Coll Cardiol. 30 (3), 1997, 613-20.
PubMed
7) Akasaka, T. et al. Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol. 30 (4), 1997, 935-41.
PubMed

Chapter 2 心嚢穿刺後に急変 ! ? まさか、心 "臓" 穿刺… ?

P.55 掲載の参考文献
1) Roy, CL. et al. Does this patient with a pericardial effusion have cardiac tamponade? JAMA. 297 (16), 2007, 1810-8.
PubMed
2) Maggiolini, S. et al. Efficacy and complications of pericardiocentesis by real-time echo-monitored procedure. Am J Cardiol. 117 (8), 2016, 1369-74.
PubMed
3) Tsang, TS. et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses : clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc. 77, 2002, 429-36.
PubMed
4) Akyuz, S. et al. Echo-guided pericardiocentesis in patients with clinically significant pericardial effusion. Outcomes over a 10-year period. Herz. 40 (Suppl 2), 2015, 153-9.
 
5) Pradhan, R. et al. Patient characteristics and predictors of mortality associated with pericardial decompression syndrome : a comprehensive analysis of published cases. Eur Heart J Acute Cardiovasc Care. 4 (2), 2015, 113-20.
PubMed
6) Imazio, M. Pericardial decompression syndrome : A rare but potentially fatal complication of pericardial drainage to be recognized and prevented. Eur Heart J Acute Cardiovasc Care. 4 (2), 2015, 121-3.
PubMed
7) Ristic', AD. et al. Triage strategy for urgent management of cardiac tamponade : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 35 (34), 2014, 2279-84.
 
8) Klimis, H. et al. A case of persistent right ventricular failure after rapid decompression of a large chronic pericardial effusion. CASE (Phila). 2 (4), 2018, 142-6.
PubMed
9) Mukai, K. et al. The incidence of secondary tumors of the heart and pericardium : A 10-year study. Jpn J Clin Oncol. 18, 1998, 195-201.
 
10) Grover, S. et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy : a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol. 68 (6), 2013, 5465-7.
 
P.63 掲載の参考文献
1) Claude, SB. Two cardiac compression triads. JAMA. 104, 1935, 714-6.
 
2) Roy, CL. et al. Does this patient with a pericardial effusion have cardiac tamponade? JAMA. 297, 2007, 1810-8.
PubMed

Chapter 3 B型解離で一安心 ?

P.82 掲載の参考文献
1) Erbel, R. et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases : Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 35 (41), 2014, 2873-926.
 
2) Fann, JI. et al. Treatment of patients with aortic dissection presenting with peripheral vascular complications. Ann Surg. 212 (6), 1990, 705-13.
PubMed
3) Boley, SJ. et al. Circulatory responses to acute reduction of superior mesenteric artrial blood flow. Physiologist. 12, 1969, 180.
 
4) Menke, J. Diagnostic accuracy of multidetector CT in acute mesenteric ischemia : systematic review and meta-analysis. Radiology. 256 (1), 2010, 93-101.
PubMed
5) Haglund, U. et al. Intestinal ischemia : the basics. Langenbecks Arch Surg. 384 (3), 1999, 233-8.
PubMed
6) Sartini, S. et al. Duplex ultrasound in the early diagnosis of acute mesenteric ischemia : a longitudinal cohort multicentric study. Eur J Emerg Med. 24 (6), 2017, e21-6.
PubMed
7) Moneta, GL. Screening for mesenteric vascular insufficiency and follow-up of mesenteric artery bypass procedures. Semin Vasc Surg. 14 (3), 2001, 186-92.
PubMed
8) Rami, O. et al. Optimal treatment of uncomplicated type B aortic dissection : JACC Review Topic of the Week. J Am Coll Cardiol. 74, 2019, 1494-504.
 
P.87 掲載の参考文献
1) 山崎武俊ほか. 西洋薬による症状コントロールが困難な冠攣縮性狭心症に対して四逆散と桂枝茯苓丸の併用が有効であった2症例. 日本東洋医学雑誌. 65, 2014, 287-94.
 
2) Nishida, S. et al. Vascular pharmacology of Mokuboito (Mu-Fang-Yi-Tang) and its constituents on the smooth muscle and the endothelium in rat aorta. eCAM. 4, 2007, 335-41.
 
3) Ezaki, H. et al. Effects of Mokuboito, a Japanese Kampo medicine, on symptoms in patients hospitalized for acute decompensated heart failure-A prospective randomized pilot study. J Cardiology. 74 (5), 2019, 412-7.
 
4) Miho, E. et al. Acute and chronic effects of mokuboito in a patient with heart failure due to severe aortic regurgitation. Fukushima J Med Sci. 65 (2), 2019, 61-7.
 
5) 礒濱洋一郎. 漢方薬の利水作用とアクアポリン. ファルマシア. 47, 2011, 1117-20.
 
6) 玉野雅裕ほか. トルバプタンノンレスポンダー心不全患者における五苓散併用効果の臨床的検討. Progress in Medicine. 37, 2017, 777-82.
Medical*Online
7) 北村順. これからの循環器診療に役立つ漢方薬処方テキスト. 東京, 文光堂, 2020, 42-59.
 

Chapter 4 骨折と心不全の不思議な関係

P.96 掲載の参考文献
1) Gompels, BM. et al. Correlation of radiological manifestations of multiple myeloma with immunoglobulin abnormalities and prognosis. Radiology. 104 (3), 1972, 509-14.
PubMed
2) Law, IP. et al. Letter : IgA myeloma and sternal fracture. JAMA. 223 (7), 1975, 767-8.
 
3) Kintzer, JS Jr. et al. Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med. 138 (5), 1978, 727-30.
PubMed
4) Ippolito, D. et al. Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM). Eur J Radiol. 82 (12), 2013, 2322-7.
PubMed
5) Bockorny, M. et al. Severe heart failure after Bortezomib treatment in a patient with multiple myeloma : A case report and review of the literature. Acta Haematol. 128, 2012, 244-7.
 
6) Bahlis, NJ. et al. Multiple myeloma-associated AL amyloido-sis : Is a distinctive therapeutic approach warranted? Bone Marrow Transplant. 38, 2006, 7-15.
 
P.101 掲載の参考文献
1) Hoffmann, TC. et al. The Connection Between Evidence-Based Medicine and Shared Decision Making. JAMA. 312 (13), 2014, 1295-6.
PubMed
2) Schichtel, M. et al. The Effect of Advance Care Planning on Heart Failure : a Systematic Review and Meta-analysis. J Gen Intern Med. 2019. [Epub ahead of print]
 
3) Murray, SA. et al. Illness trajectories in Palliative care. BMJ. 330 (7498), 2005, 1007-11.
PubMed
4) Lee, DS. et al. Prediction of heart failure mortality in emergent care : a cohort study. Ann Intern Med. 156 (11), 2012, 767-75.
 
5) Pocock, SJ. et al. Predicting survival in heart failure : a risk score based on 39 372 patients from 30 studies. Eur Heart J. 34 (19), 2013, 1404-13.
 
6) Anderson, F. et al. Palliative performance scale (PPS) : a new tool. J Palliat Care. 12 (1), 1996, 5-11.
PubMed
7) Morita, T. et al. The Palliative Prognostic Index : a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer. 7 (3), 1999, 128-33.
PubMed
8) Allen, LA. et al. Decision making in advanced heart failure : a scientific statement from American Heart Association. Circulation. 125 (15), 2012, 1928-52.
PubMed

Chapter 5 左房に浮かぶ2つの物体 "いつとるの ? 今でしょ ! "

P.116 掲載の参考文献
1) Abe, Y. et al. Prediction of embolism in atrial fibrillation : Classification of left atrial thrombi by transesophageal echocardiography. Jpn Circ J. 64, 2000, 411-5.
PubMed
2) Ogata, C. et al. Cauliflower-like giant left atrial thrombus successfully treated by anticoagulants without systemic complication : a case report cauliflower-like giant left atrial thrombus successfully treated by anticoagulants without systemic complication : a case report. J Cardiol. 41 (6), 2003, 291-5.
PubMed
3) Vitale, N. et al. Asymptomatic large left- atrial ball thrombus : Secondary to mitral stenosis. Tex Heart Inst J. 24, 1997, 376-8.
 
4) Heppell, RM. et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 77, 1997, 407-11.
PubMed
5) Sonoda, M. et al. Multiple atrial ball thrombi with stalk mimicking myxoma without valve disease : A Case Report. J Cardiol. 4 (95), 2007, 287-93.
 
6) Faustino, A. et al. Atypical atrial myxoma pending to the left atrial appendage : a diagnostic challenge. BMJ Case Rep. 2013, bcr2012007850.
 
7) Sahratov, H. et al. Left atrial appendage mass : is it always a thrombus? Kardiochir Torakochirurgia Pol. 13 (4), 2016, 359-60.
PubMed
8) Malik, L. et al. Left atrial appendage myxoma masquerading as left atrial appendage thrombus. Asian Cardiovasc Thorac Ann. 21 (2), 2013, 205-7.
PubMed
9) 脇屋義彦ほか. 臨床 心血管造影による左房内血栓の診断 : 選択的冠動脈造影を中心に. 心臓. 15 (4), 1983, 447-53.
 
10) Abbas, A. et al. Cardiac MR assessment of cardiac myxomas. Br J Radiol. 88 (1045), 2015, 20140599.
PubMed
P.122 掲載の参考文献
1) Khalid, I. et al. Early enteral nutrition and outcomes of critically ill patients treated with vasopressors and mechanical ventilation. Am J Crit Care. 19 (3), 2010, 261-8.
 
2) Reignier, J. et al. Enteral versus parenteral early nutrition in ventilated adults with shock : a randomized, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2). Lancet. 391, 2018, 133-43.
 
3) Venkateswaran, RV. et al. Lethal mesenteric ischaemia after cardiopulmonary bypass : a common complication? Eur J Cardiothor Surg. 22, 2002, 534-8.
 
4) McClave, SA. et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient : Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 40 (2), 2016, 159-211.
 
5) 日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会. 日本版重症患者の栄養療法ガイドライン. 日本集中治療医学会雑誌. 23, 2016, 185-281.
 
6) 寺島秀夫. 侵襲急性期におけるエネルギー投与のパラダイムシフト : 内因性エネルギー供給を考慮した理論的エネルギー投与法の提言. 日本集中治療医学会雑誌. 20, 2013, 359-67.
 
7) Casaer, MP. et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 365 (6), 2011, 506-17.
PubMed
8) 東別府直紀ほか. 本邦ICUでのエネルギー充足率と転帰への影響. 日本集中治療医学会雑誌. 26, 2019, 25-7.
 
9) Koekkoek, WAC. et al. Timing of PROTein INtake and clinical outcomes of adult critically ill patients on prolonged mechanical VENTilation : The PROTINVENT retrospective study. Clin Nutr. 38 (2), 2019, 883-90.
PubMed
10) Vanhorebeek, I. et al. Effect of early supplemental parenteral nutrition in the paediatric ICU : a preplanned observational study of post-randomisation treatments in the PEPaNIC trial. Lancet Respir Med. 5 (6), 2017, 475-83.
PubMed
11) Heyland, DK. et al. Glutamine and antioxidants in the critically ill patient : a post hoc analysis of a large-scale randomized trial. JPEN J Parenter Enteral Nutr. 39 (4), 2015, 401-9.
 
12) Zhu, R. et al. The effect of IV amino acid supplementation on mortality in ICU patients may be dependent on kidney function : Post hoc subgroup analyses of a multicenter randomized trial. Crit Care Med. 46 (8), 2018, 1293-301.
PubMed
13) Ohbe, H. et al. Early enteral nutrition for cardiogenic or obstructive shock requiring venoarterial extracorporeal membrane oxygenation : A nationwide inpatient database study. Intensive Care Med. 44 (8), 2018, 1258-65.
PubMed
14) Sze, S. et al. Prevalence and prognostic significance of malnutrition using 3 scoring systems among outpatients with heart failure : a comparison with body mass index. JACC Heart Fail. 6 (6), 2018, 476-86.
PubMed
15) Milajerdi, A. et al. Pre-and post-diagnosis body mass index and heart failure mortality : a doseresponse meta-analysis of observational studies reveals greater risk of being underweight than being overweight. Obes Rev. 20 (2), 2018, 252-61.
 
16) 日本心不全学会ガイドライン委員会. 心不全患者における栄養評価・管理のステートメント. http://www.asas.or.jp/jhfs/pdf/statement20181012.pdf accessed on 20th June 2020. (2021年1月閲覧)
 
17) Anker, SD. et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors : an observational study. Lancet. 361 (9363), 2003, 1077-83.
PubMed
18) Lakdawalla D N. et al. Can oral nutritional supplements improve medicare patient outcomes in the hospital? Forum Health Econ Policy. 17 (2), 2014, 131-51.
PubMed
19) Schuetz, P. et al. Individualised nutritional support in medical inpatients at nutritional risk : a randomised clinical trial. Lancet. 393 (10188), 2019, 2312-21.
 

Chapter 6 突然の胸痛、そんなとこ裂けるの ! ?

P.131 掲載の参考文献
1) Kreibich, M. et al. Aneurysms of the pulmonary artery. Circulation. 131 (3), 2015, 310-6.
PubMed
2) Khattar, RS. et al. Pulmonary artery dissection : an emerging cardiovascular complication in surviving patients with chronic pulmonary hypertension. Heart. 91 (2), 2005, 142-5.
PubMed

Chapter 7 水に浮かぶ心臓。その理由は ?

P.141 掲載の参考文献
1) Petri, M. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64 (8), 2012, 2677-86.
PubMed
2) Sagrista-Sauleda, J. et al. Clinical clues to the causes of large pericardial effusions. Am J Med. 109 (2), 2000, 95-101.
 
3) Little, WC. et al. Pericardial disease. Circulation. 113 (12), 2006, 1622-32.
PubMed
4) Meyers, DG. et al. The usefulness of diagnostic tests on pericardial fluid. Chest. 111 (5), 1997, 1213-21.
PubMed
5) 松本美富士. 膠原病の心膜, 心筋病変. 医学のあゆみ. 173, 1995, 132-5.
 
6) Griffiths, B. et al. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 19, 2005, 685-708.
 
7) Matthew, H. et al. Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus : report of a consensus meeting. Arthritis Rheum. 50 (11), 2004, 3427-31.
 
8) Feng, D. et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy : a pilot study. Circulation. 124 (17), 2011, 1830-7.
PubMed
P.147 掲載の参考文献
1) Mason, JC. et al. Cardiovascular disease in patients with chronic inflammation : mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 36 (8), 2015, 482-9.
PubMed
2) Cobb, S. et al. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 249, 1953, 553-6.
PubMed
3) Hollan, I. et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 12, 2013, 1004-15.
PubMed
4) Dregan, A. et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke : a population-based cohort study. Circulation. 130 (10), 2014, 837-44.
PubMed
5) Soto, ME. et al. Coronary CT angiography in Takayasu arteritis. JACC Cardiovasc Imaging. 4 (9), 2011, 958-66.
PubMed
6) Cohen, TJW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol. 27 (1), 2013, 33-44.
 
7) Yamanaka, H. et al. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Modern Rheumatol. 24 (1), 2014, 33-40.
 
8) Kubota, K. et al. Epidemiology of psoriasis and palmoplantar pustulosis : a nationwide study using the Japanese national claims database. BMJ Open. 5, 2015, e006450.
PubMed
9) Yamamoto, T. et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol. 43 (10), 2016, 1193-6.
PubMed
10) Gonzalez, A. et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 56 (11), 2007, 3583-7.
PubMed
11) Naz, SM. et al. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 21 (5), 2007, 871-83.
PubMed
12) Avina-Zubieta, JA. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis : a meta-analysis of observational studies. Arthritis Rheum. 59 (12), 2008, 1690-7.
PubMed
13) Narnjo, A. et al. Cardiovascular disease in patients with rheumatoid arthritis : results from the QUEST-RA study. Arthritis Res Ther. 10 (2), 2008, R30.
PubMed
14) Johnsen, SP. et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs : a population-based case-control study. Arch Intern Med. 165 (9), 2005, 978-84.
PubMed
15) Juni, P. et al. Risk of cardiovascular events and rofecoxib : cumulative meta-analysis. Lancet. 364 (9450), 2004, 2021-9.
PubMed
16) Suissa, S. et al. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum. 55 (4), 2006, 531-6.
PubMed
17) Solomon, DH. et al. Immunosuppressive Medications and Hospitalization for Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Rheum. 54 (12), 2006, 3790-8.
PubMed
18) Eugene, S. et al. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure. Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation. 107, 2003, 3133-40.
 
19) Urowitz, MB. et al. The Bimodal Mortality Pattern of Systemic Lupus Erythematosus. Am J Med. 60 (2), 1976, 221-5.
PubMed
20) Rubib, LA, et al. Mortality in Systemic Lupus Erythematosus : The Bimodal Pattern Revisited. Q J Med. 55 (216), 1985, 87-98.
 
21) Manzi, S. et al. Age-specific Incidence Rates of Myocardial Infarction and Angina in Women With Systemic Lupus Erythematosus : Comparison With the Framingham Study. Am J Epidemiol. 145, 1997, 408-15.
PubMed
22) Roman, MJ. et al. Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. N Engl J Med. 349, 2003, 2399-406.
PubMed
23) Roman, MJ. et al. Rate and Determinants of Progression of Atherosclerosis in Systemic Lupus Erythematosus. Arthritis Rheum. 56 (10), 2007, 3412-9.
PubMed
24) Asanuma, Y. et al. Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus. N Engl J Med. 349, 2003, 2407-15.
PubMed
25) Steen, VD. et al. Changes in Causes of Death in Systemic Sclerosis, 1972-2002. Ann Rheum Dis. 66, 2007, 40-4.
 
26) 桑名正隆. 強皮症における血管内皮前駆細胞異常. Jpn J Clin Immunol. 36 (1), 2013, 17-26.
 
27) Iudici, M. et al. Pulmonary hypertension in systemic sclerosis : prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clin Exp Rheumatol. 31 (2 Suppl 76), 2013, 31-6.
 

Chapter 8 繰り返す急性肺水腫 その原因は ?

P.159 掲載の参考文献
1) David, A. et al. Resistant hypertension : Diagnosis, Evaluation, and Treatment a scientific statement from the american heart association professional education committee of the council for high blood pressure research. Hypertension. 51, 2008, 1403-19.
 
2) AG, Logan. et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertension. 2001, 19, 2271-7.
 
3) Pasupathy, S. et al. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circ. 131 (10), 2015, 861-70.
 
4) Yasue, H. et al. Long-term prognosis for patients with variant angina and influential factors. Circulation. 78, 1998, 1-9.
 
5) Nishi, I. Effects of Anti-vasospastic Agents in Japanese Patients with Dilated Cardiomyopathy and Coronary Vasospasm. Jpn Heart J. 43, 2002, 333-42.
PubMed
6) Inami, T. et al. Left ventricular dysfunction due to diffuse multiple vessel coronary artery spasm can be concealed in dilated cardiomyopathy. Eur Heart J Fail. 14, 2012, 1130-8.
 
7) Sueda, S. et al. Vasospastic heart failure : Multiple spasm may cause transient heart failure? J Cardiology. 54, 2009, 452-9.
 
P.165 掲載の参考文献
1) Sueda, S. et al. Acetylcholine spasm provocation test by trans-radial artery and brachial vein approach. Cather Cardiovasc Interv. 94 (1), 2019, 38-44.
 
2) Sueda, S. Is there no probrem with diagnosis of vasospastic angina in the clinic? : We should learn a case who was admitted to our hospital from a distant place. Coron Artery Dis. 2020, 26, 69-73.
 
3) Sueda, S. et al. Gender differences in sensitivity of acetylchioline and ergonovine to coronary spasm provocation test. Heart Vessels. 31 (3), 2016, 322-9.
PubMed
4) Yasue, H. et al. Coronary artery spasm : Clinical features, diagnosis, pathogenesis, and treatment. J Cardiol. 51 (1), 2008, 2-17.
PubMed
5) 末田章三. たかが冠攣縮, されど冠攣縮. 大阪, メディカ出版, 2016, 160p. (CIRCULATION Up-to-Date Books 15)
 
6) Sueda, S. et al. Overview of complications during pharmacological spasm provocation tests. J Cardiol. 68 (1), 2016, 1-6.
PubMed
7) Sueda, S. et al. Overview of the pharmacological spasm provocation test : Comparisons between aceylcholine and ergonovine. J Cardiol. 69 (1), 2017, 57-65.
 
8) JCS joint working group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary spastic angina) (JCS 2013). Circ J. 78, 2014, 2779-801.
 

Chapter 9 心不全の裏ボスを暴け ! ～ACS症例で考えること～

P.178 掲載の参考文献
1) Elbadawi, A. et al. Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. JACC Cardiovasc Interv. 12, 2019, 1825.
PubMed
2) Kishon, Y. et al. Mitral valve operation in postinfarction rupture of a papillary muscle : immediate results and long-term followup of 22 patients. Mayo Clin Proc. 67, 1992, 1023-30.
 
3) Kasliwal, RR. et al. "mechanical complications of acute myocardial infarction". Applied echocardiography in coronary artery disease. INDIA, Jaypee Brothers Medical, 2017, 143-4.
 
4) Ternus, BW. et al. Clinical presentation and echocardiographic diagnosis of postinfarction papillary muscle rupture : A review of 22 cases. Echocardiography. 34, 2017, 973-7.
PubMed
5) Bursi, F. et al. Heart failure and death after myocardial infarction in the community : the emerging role of mitral regurgitation. Circulation. 111, 2005, 295.
PubMed
6) Havins, J. et al. Real time three : dimensional transesophageal echocardiography in partial posteromedial papillary muscle rupture. Echocardiography. 30, 2013, E179-81.
PubMed
7) Nishimura, RA. et al. Two dimensional echocardiographic diagnosis of partial papillary muscle rupture. Br Heart J. 48, 1982, 598-600.
PubMed
P.187 掲載の参考文献
1) Fallick, C. et al. Sympathetically mediated changes in capacitance : redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail. 4, 2011, 669-75.
PubMed
2) Shibagaki, Y. et al. Significant reduction of the large-vessel blood volume by food intake during hemodialysis. Clin Nephrol. 49, 1998, 49-54.
PubMed
3) Fudim, M. et al. Splanchnic Nerve Block for Acute Heart Failure. Circulation. 138, 2018, 951-3.
PubMed
4) Fujita, T. et al. Hemodilution after Initial Treatment in Patients with Acute Decompensated Heart Failure. Int Heart J. 59, 2018, 573-9.
PubMed
5) Parati, G. et al. Heart failure and sleep disorders. Nat Rev Cardiol. 13, 2016, 389-403.
PubMed
6) Matsue, Y. et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 69, 2017, 3042-51.
PubMed
7) Felker, GM. et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 364, 2011, 797-805.
PubMed
8) Inomata, T. et al. Effects of additive tolvaptan vs. Increased furosemide on heart failure with diuretic resistance and renal impairment-results from the K-STAR Study. Circ J. 82, 2017, 159-67.
 
9) Bradley, A. et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 367, 2012, 2296-304.
 

Chapter 10 あなたならどうする、すぐに手術 ? それとも…

P.198 掲載の参考文献
1) Kasashima, S. et al. Inflammatory abdominal aortic aneurysm : close relationship to IgG4-related periaortitis. Am J Surg Pathol. 32, 2008, 197-204.
PubMed
2) Rehring, TF. et al. Regression of perianeurysmal fibrosis and ureteral dilatation following endovascular repair of inflammatory abdominal aortic aneurysm. Ann Vasc Surg. 15, 2001, 591-3.
 
3) Ruppert, V. et al. Endovascular repair of inflammatory abdominal aortic aneurysms : a valuable alternative? Case report and review of literature. Ann Vasc Surg. 18, 2004, 357-60.
PubMed
4) Paravastu, SC. et al. A systematic review of open versus endovascular repair of inflammatory abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 38, 2009, 291-7.
PubMed
5) Eriksen, TF. et al. Treatment with corticosteroids and the risk of anastomotic leakage following lower gastrointestinal surgery : a literature survey. Colorectal Dis. 16 (5), 2014, 154-60.
 
6) Walker, DI. et al. Inflammatory aneurysm of the abdominal aorta. Br J Surg. 59, 1972, 609-14.
PubMed
7) 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告). 大動脈瘤・大動脈解離診療ガイドライン (2011年改訂版). https://www.j-circ.or.jp/old/guideline/pdf/JCS2011_takamoto_h.pdf (2021年1月閲覧)
 
8) Osler, W. The Gulstonian lectures on malignant endocarditis. Br Med J. 1, 1885, 467-70.
 
9) Oskoui, R. et al. Salmonella aortitis. A report of a successfully treated case with a comprehensive review of the literature. Arch intern Med. 153, 1993, 517-25.
PubMed

Chapter 11 どっちの治療が先 ?

P.213 掲載の参考文献
1) 日本サルコイドーシス/肉芽腫生疾患学会. サルコイドーシス診療の手引き 2018. https://www.jssog.com/journal (2021年1月閲覧)
 
2) 日本循環器学会ほか. 2014-2015年度活動. 心臓サルコイドーシスの診療ガイドライン (2016年版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_terasaki_h.pdf (2021年1月閲覧)
 
3) Yazaki, Y. et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 88, 2001, 1006-10.
PubMed
4) 加藤靖周ほか. 心臓サルコイドーシスにおける房室伝導障害. 日本サルコイドーシス/肉芽腫性疾患学会雑誌. 31, 2011, 66-72.
Medical*Online
5) Greulich, S. et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 6, 2013, 501-11.
PubMed
P.219 掲載の参考文献
1) Rudolph, A. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J AM Coll Cardiol. 2009, 53 (3), 284-91.
PubMed
2) De Cobelli, F. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol. 2009, 192, 97-102.
 

Chapter 12 突然の呼吸困難・ショック、次の一手はもちろん…カテコラミン ? ?

P.228 掲載の参考文献
1) Panza, JA. et al. Valvular aortic stenosis and asymmetric septal hypertrophy : diagnostic considerations and clinical and therapeutic implications. Eur Heart J. 9 Suppl E, 1988, 71-6.
 
2) Tasca, G. et al. Myectomy-myotomy associated with aortic valve replacement for aortic stenosis : effects on left ventricular mass regression. Ital Heart J. 4 (12), 2003, 865-71.
PubMed
3) Suh, WM. et al. Suicide left ventricle following transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 76 (4), 2010, 616-20.
PubMed
4) Tsuruta, H. et al. Incidence, predictors, and midterm clinical outcomes of left ventricular obstruction after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 92 (4), 2018, E288-98.
PubMed

Chapter 13 発熱、腰痛といえば解熱鎮痛薬 ! ? 聴診してます ?

P.244 掲載の参考文献
1) Nakatani, S. et al. Recent picture of infective endocarditis in Japan-lessons from Cardia Disease Registration (CADRE-IE). Circ J. 77, 2013, 1558-64.
 
2) 循環器病の診断と治療に関するガイドライン (2016-2017年度活動). 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/old/guideline/pdf/JCS2017_nakatani_h.pdf (2021年1月閲覧)
 
3) Alexiou, C. et al. Surgery for active culture-positive endocarditis : determinants of early and late outcome. Ann Thorac Surg. 69, 2000, 1448-54.
PubMed
4) Kang, DH. et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 366, 2012, 2466-73.
PubMed
5) Garcia-Cabrera, E. et al. Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases. Neurological complications of infective endocarditis : risk factors, outcome, and impact of cardiac surgery : a multicenter observational study. Circulation. 127, 2013, 2272-84.
 
6) Hess, A. et al. Brain MRI findings in neurologically asymptomatic patients with infective endocarditis. AJNR Am J Neuroradiol. 34, 2013, 1579-84.
PubMed
7) Ebright, JR. et al. Splenic Infarction and Abscess in the Setting of Infective Endocarditis : A Review of Diagnostic Methods and Management. Infect Dis Clin Pract. 15, 2007, 17-21.
 
8) Murillo, O. et al. Endocarditis associated with vertebral osteomyelitis and septic arthritis of the axial skeleton. Infection. 46, 2018, 245-51.
PubMed
9) Akiyama, T. et al. Incidence and risk factors for mortality of vertebral osteomyelitis : a retrospective analysis using the Japanese diagnosis procedure combination database. BMJ open. 3, 2013.
PubMed
P.249 掲載の参考文献
1) Nakatani, S. et al. JCS 2017 guideline on prevention and treatment of infective endocarditis. Circ J. 83 (8), 2019, 1767-809.
 
2) Baddour, LM. et al. Infective Endocarditis in Adults : Diagnosis, Antimicrobial Therapy, and Management of Complications : A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 132 (15), 2015, 1435-86.
PubMed
3) The 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 36 (44), 2015, 3036-7.
PubMed
4) Habib, G. et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol. 33, 1999, 2023-29.
 
5) Evangelista, A. et al. Echocardiography in infective endocarditis. Heart. 90 (6), 2004, 614-7.
PubMed
6) Mgbojikwe, N. et al. Infective endocarditis : Beyond the usual tests. Cleve Clin J Med. 86 (8), 2019, 559-67.
PubMed
7) Salaun, E. et al. Beyond Standard Echocardiography in Infective Endocarditis : Computed Tomography, 3-Dimensional Imaging, and Multi-Imaging. Circ Cardiovasc Imaging. 11 (3), 2018, e007626.
PubMed
8) Kouijzer, IJE. et al. The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging. 40 (7), 2013, 1102-7.
 
9) Regueiro, A. et al. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA. J Am Med Assoc. 316 (10), 2016, 1083-92.
 
10) Kuttamperoor, F. et al. Infectious Endocarditis after Transcatheter Aortic Valve Replacement : Epidemiology and Outcomes. Cardiol Rev. 27 (5), 2019, 236-41.
PubMed
11) Mihos, CG. et al. Surgical Versus Medical Therapy for Prosthetic Valve Endocarditis : A Meta-Analysis of 32 Studies. Ann Thorac Surg. 103 (3), 2017, 991-1004.
PubMed
12) Loverix, L. et al. Prosthetic endocarditis after transcatheter aortic valve implantation : Pooled individual patient outcome. Int J Cardiol. 178 (2015), 2015, 67-8.
PubMed
13) Ruch, Y. et al. Impact of Setting up an "endocarditis Team" on the Management of Infective Endocarditis. Open Forum Infect Dis. 6 (9), 2019, 1-7.
 

Chapter 14 ただの風邪だと思っていたのに

P.266 掲載の参考文献
1) Sawada, K. et al. Predicting parameters for successful weaning from veno‐arterial extracorporeal membrane oxygenation in cardiogenic shock. ESC Heart Fail. 8, 2021, 471-480.
 
2) Isogai, T. et al. Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality : propensity score analyses. J Card Fail. 5, 2015, 391-7.
PubMed
3) Huang, X. et al. Intravenous Immunoglobulin Therapy for Acute Myocarditis in Children and Adults. Int Heart J. 60 (2), 2019, 359-65.
PubMed
4) Fox, H. et al. Fulminant myocarditis managed by extracorporeal life support (Impella(R) CP) : a rare case. Case Rep Cardiol. 2017, 2017, 9231959.
 
5) Asaumi, Y. et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J. 26, 2005, 2185-92.
PubMed
6) Chong, S2. et al. Associations with the in-hospital survival following extracorporeal membrane oxygenation in adult acute fulminant myocarditis. J Clin Med. 7 (11), 2018, 452.
 
7) Matsumoto, M. et al. Clinical determinants of successful weaning from extracorporeal membrane oxygenation in patients with fulminant myocarditis. ESC Heart Failure. 5, 2018, 675-84.
PubMed
P.273 掲載の参考文献
1) Scheidt, S. et al. Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical trial. N Engl J Med. 288, 1973, 979-84.
PubMed
2) Stone, GW. et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators. J Am Coll Cardiol. 29, 1997, 1459-67.
PubMed
3) Patel, MR. et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock : the CRISP AMI randomized trial. JAMA. 306, 2011, 1329-37.
PubMed
4) Thiele, H. et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 367, 2012, 1287-96.
PubMed
5) Ibanez, B. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 39, 2017, 119-77.
 
6) 川上将司. 明日のアクションが変わる循環器救急の真髄教えます. 東京, 中外医学社, 2017, 418p.
 
7) 川上将司. 明日のアクションが変わる補助循環の極意教えます. 東京, 中外医学社, 2018, 422p.
 
8) Sakamoto, T. et al. Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with out-of-hospital cardiac arrest : a prospective observational study. Resuscitation. 85, 2014, 762-8.
PubMed

書評

最近チェックした商品履歴

Loading...